The authors show by illustration that procedures used to validate the reliability of single-concentration high-throughput screens such as the signal window and Z′ factor do not ensure sufficient reliability in potency estimates from concentration response assays. They develop the minimum significant ratio as a statistical parameter to characterize the fold change between 2 compounds run in the same experiment that can be considered a real difference and use this parameter to characterize the reliability of the assay. They adapt methods described by Bland and Altman to develop a simple set of 2 experiments to estimate the minimum significant ratio and show that this protocol can identify assays that lack reproducibility. The methods are then extended to validate the equivalency of the same assay run by multiple laboratories. (Journal of Biomolecular Screening 2006:253-261) 
INTRODUCTION

P
R O C E D U R E S TO VALIDATE the reliability of singleconcentration high-throughput screens (HTS) such as the signal window and Z′ factor are well established. [1] [2] [3] [4] Use of such procedures establishes that the HTS will have acceptable rates of false positives and negatives. Confirmation assays, and subsequent structure-activity relationship (SAR) activities to develop the lead molecules into clinical candidates following the HTS, are usually concentration-response assays to estimate the in vitro potency and/ or efficacy of these molecules. The HTS criteria are useful for monitoring the ongoing stability of the controls but are not by themselves sufficient to establish reliable estimates of potency. Note that potency is used here generically and typically is the EC 50 , IC 50 , K i , or K b , depending on the nature of the assay and target. In the next section, we illustrate the insufficiency of singleconcentration parameters by an example of a binding assay for NPY2 developed for SAR work. In the 3rd section, we propose a new statistical measure to validate the reliability of potency estimates from concentration-response assays. Moreover, follow-up work often occurs in different laboratories than the HTS laboratory, and therefore methods are required to validate the equivalence of the assay results across laboratories. In the 4th section, we extend the methods of the 3rd section to cover transferring assays across laboratories.
NPY2 BINDING ASSAY VALIDATION
Materials: NPY2 binding assay
NPY was purchased from American Peptide Company (Sunnyvale, CA). Iodinated PYY was purchased from NEN (Boston, MA). CHO rh Y2 membrane cells were prepared in house.
Binding affinity for NPY2 antagonists
IC 50 values were estimated in a high-volume testing protocol using automated dilutions of inhibitors (3-fold dilutions of 11 concentrations performed in singletons) into 96-well plates and transferred to MAFB filter plates. The assay protocol was 20 µl of inhibitor solution (35 µl inhibitor test solution [1 mM concentration in DMSO] + 245 µl buffer [2 g/l bacitracin in 25 mM HEPES, 2.5 mM CaCl 2 , 1 mM MgCl 2 ]), 50 µl 0.25 nM 125 I-PYY, and 180 µl membranes (15 µg/well). Plates were then incubated for 2 h at room temperature. A total of 200 µl was transferred to filter plates presoaked in 0.5% PEI for 15 min. Plates were then aspirated with the MAP aspirator. A total of 100 µl scintillant was added to the filter plates. Plates were sealed and incubated for 30 min at room temperature. Plates were read in a Topcount plate reader using a preprogrammed protocol.
IC 50 values were estimated from a 4-parameter logistic fit of percentage activity versus concentration. Curves with an incomplete dose response could be refit fixing either the top at 100% or the bottom at 0% as required. Points deemed to be outliers could be excluded from the analysis. For each day of each test, the signal window, Z′ factor, and percentage specific binding were computed by amalgamating all plate total and nonspecific wells together into a single calculation for the run.
NPY2 replicate results
To examine the reproducibility of the assay results, 32 compounds of varying potency were tested in 2 independent runs of the assay. Aggregate signal window, Z′ factor, and percentage specific binding values are shown in Table 1 , labeled as "study 1." All statistics are at acceptable levels. The 4-parameter logistic model estimates are shown in Table 2 . Of the 32 compounds, 29 compounds in run 1, 27 compounds in run 2, and 25 compounds in both runs had reportable IC 50 values.
By visual inspection of Table 2 , reproducibility problems are evident. For example, compounds P1-6 (IC 50 estimates of 7.47 nM on run 1 and 3017 nM on run 2), P5-5 (log-IC 50 estimates of 6882 nM on run 1 and 16 nM on run 2), and P5-7 (IC 50 estimates of 13.4 nM on run 1 and 5026 nM on run 2) all differ by greater than 100-fold across the 2 runs. Five of the 25 compounds for which both runs yielded reportable results have results differing by more than 10-fold. These results are clearly unacceptable for SAR work, yet the HTS statistics are all at acceptable levels.
The assay was assessed for problems, and it was speculated that the problems were due to the pipetting methods used to create the assay plates. A Multimek pipettor, along with a more robust compound dilution scheme, replaced the initial procedure. The same compounds were run in a 2nd set of paired trials, and the results are shown in Table 3 . Reportable IC 50 values were obtained for 30 of 32 compounds in the 1st run, 29 of 32 compounds in the 2nd run, and 29 of 32 compounds in both runs. The assay is now clearly performing acceptably, as the ratio of IC 50 s for all compounds is less than 3-fold and is less than 2-fold for 25 of the 29 compounds. The signal window, Z′ factor, and percentage specific binding are shown in Table 1 , labeled as "study 2." Although the signal window and Z′ factor are nominally better than in the 1st trial, only the 2nd run in study 2 showed a statistical improvement. 4 The signal windows and Z′ factors were acceptable in both studies. We therefore conclude that HTS statistics do not ensure acceptable performance in concentration-response work. In the next section, we introduce a new statistic to quantify reproducibility of potency estimates derived from concentration-response assays and introduce a simple experimental protocol to estimate this outcome. 
RELIABILITY IN CONCENTRATION-RESPONSE ASSAYS
Minimum significant ratio
Eastwood and others 5 showed that if log potency estimates are normally distributed and σ is the population standard error for a compound's log potency evaluated in a particular assay run, then the 2 compounds evaluated in the same physical run have a statistically significant difference if the ratio of potencies (largest to smallest) exceeds 10^(Z α2 2σ), where Z α2 is the critical value from a standard normal distribution and α is the type I error rate. We denote the quantity 10^(Z α2 2σ) as the minimum significant ratio (MSR) and propose it as the key statistical parameter for concentration response assays. In applications, we set α = 0.05, and following the convention of Bland and Altman, 6 we round Z 0.025 to 2. Thus, we define MSR = 10^(2 2σ).
The MSR plays a key role in several aspects of assay usage. From an SAR perspective, the key requirement of the assay is to have low variation, both within and across runs. The MSR is a direct parameter of interest when comparing 2 molecules evaluated within the same run and a necessary component to having high statistical power when comparing compounds evaluated in different runs of the assay.
From a pharmacological validation perspective, a key requirement of an assay is that it can correctly rank order the potency of literature standard compounds. This requirement is usually evaluated in a set of 3 runs of the assay, and results are averaged to compare to literature values to ascertain if the assay can correctly rank order the potency values. For success to occur, the within-run assay variation has to be sufficiently small, which is met if the assay has a sufficiently small MSR. Another pharmacological requirement is that assay affinity estimates from one assay should correlate to affinity estimates from other assays assessing activity on the same target. For example, a binding assay assessing affinity of molecules for a particular receptor should correlate to a functional assay assessing affinity on the same target. This requirement is also met if the assay variation of both assays is sufficiently small. Note that in many instances of interassay comparisons, it is required not only that the 2 assays have a high correlation but also that the affinity estimates are equal in the 2 assays. In those cases, one can use the interlaboratory assessment techniques described in the 4th section and in Sun and others' work 7 to assess this requirement.
Replicate-experiment protocol to estimate the MSR
The MSR statistic depends on σ, the population standard error of the log potency estimates. One needs to obtain an estimate of this value to assess assay reliability. The natural estimate to use would be the standard error reported by the nonlinear regression program. However, these estimates can underestimate the true assay variation by a considerable amount and therefore are not recommended. For example, Table 4 contains the mean and maximum standard errors of the log-IC 50 estimates for each of the 2 days of each test run of the assay and the corresponding estimates of the MSR. For study 1, the largest standard error over both days gives an MSR estimate of 3.5. This clearly understates the true assay variation, as 20% of the compounds exceeded a 10-fold limit and 13 of the 25 values exceeded the 3.5-fold limit. If the nominal error rate of 5% were correct, one would expect that only 2 compounds should have a ratio of potencies outside the 3.5-fold threshold. The standard errors of the 2nd study are better than those of the 1st study but are not reflective of the dramatic improvement in assay reproducibility.
Thus, nonlinear regression standard errors are not reliable estimates of assay precision. This conclusion is not surprising, as nonlinear regression theory assumes that the wells are statistically in- dependent and that the actual compound concentration in each well is exactly equal to the nominal concentration. 8 By contrast, concentration-response assays are usually constructed by serial dilutions, and hence neither of these assumptions is met in practice. Thus, it is not surprising that the standard errors do not reflect the actual variation present in the assay.
Instead, we recommend a standard protocol to evaluate assay reproducibility. The underlying idea is an adaptation of the methods suggested by Bland and Altman 6 to compare 2 clinical measurements: evaluate a set of compounds in a single run of the assay and then reevaluate the same set of compounds in a 2nd run of the assay. So instead of comparing device 1 to device 2, we compare run 1 to run 2. The complete set of both runs we term the replicateexperiment protocol. The NPY2 data are in fact 2 runs of the entire replicate-experiment protocol.
It is admittedly counterintuitive that a pair of runs could be used to examine intrarun assay variation. We exploit the relationship between variation of paired data and variation in the individual measures. Full statistical details are described by Eastwood and others. 5 What follows below are the steps describing the analysis.
Replicate-experiment analysis
Typically, data such as the NPY2 experiments are presented as a scatterplot of measurement 1 versus measurement 2, along with a correlation coefficient summarizing the relationship between the 2 measurements. However, Bland and Altman 6 demonstrate the problems with these techniques and instead recommend that a plot of the difference in paired values be plotted against the mean of the paired values to visually examine the agreement. These techniques are best suited to normally distributed measurements with constant variability over the potency range. Because potency estimates often have a lognormal distribution, 9,10 the analysis is best done on the log scale; that is, plot the difference in log potency versus mean log potency. Alternatively, if x is the potency from the 1st assay result and y is the potency from the 2nd assay result, then plot the ratio r = xy versus the geometric mean potency, defined as gm = sqrt (x × y) = 10^[(log x + log y)2]. Figure 1 shows a ratio versus geometric mean plot for a typical set of data. Note that both axes are plotted on the log scale to reflect the distribution of that data type.
The purpose of the graph is to depict the average potency ratio between runs and also the agreement between runs for individual compound potency estimates. It should be assessed visually for any trends between potency ratio and potency value and whether the variability appears to be reasonably uniform across the potency range. Then, numerical estimates can be derived to estimate the average difference and statistically test for a difference in average potency between runs. We also derive statistical prediction limits, denoted as limits of agreement (LsA) from the Bland-Altman 6 terminology, that reflect typical boundaries for individual compound ratios. Details of the computations are as follows: Let d be the difference in log potency for each compound, and let d and s d be the sample mean and standard deviation, respectively, in log potency differences for n compounds. Then calculate Items 1, 2, and 4 are plotted as horizontal lines in Figure 1 , a solid line for MR, long dashed lines for the MR confidence limits, and short dashed lines for the LsA.
MR represents the average potency ratio across the 2 runs. Ideally, this value should be 1.0, and if the confidence limits (R L , R U ) do not include the value 1.0, then there is a statistically significant difference between runs. This can occur if random variations in the run preparation steps result in systematic differences in potency estimates between the 2 runs.
The MSR, as mentioned above, represents the largest potency ratio that can be considered a random change within a run of the assay. Note that because the assay runs are completely separate, the assay variation is statistically independent, and thus the standard deviation of the difference between the log-potency values is equal to 2 times the standard deviation of the individual measurements. Therefore, the 2 in the definition of MSR is omitted from the calculation of the MSR. The LsA represent statistical limits for individual potency ratios. If the assay were absolutely perfect, then each compound would have a potency ratio equal to 1. Assay variation that affects each compound's potency estimate individually results in points shifting above and below the MR, and assay variation that causes a systematic shift to all potency values in the run results in an MR unequal to 1. The LsA combine these 2 sources of variation to give 1 set of limits describing potency agreement between the 2 runs of the assay. Because the MSR is constructed to have a 5% error rate, typically only 5% of a sample of size 20 to 30 will lie outside these limits, and so in a sample of size 20 to 30 compounds, only 1 or 2 ratios should lie outside these limits. If there are more than 2 compounds outside the LsA, then this may indicate that the log-normal distribution assumption is not appropriate, and therefore these methods may not be applicable for that particular assay. Figures 2A and 2B, also hypothetical data from a replicateexperiment protocol, indicate assays with reliability problems. Figure 2A indicates an assay with high intrarun assay variability. There is no systematic difference between the 2 assays, but the MSR is 4.72 and the LsA are 0.16 to 3.63, which may be too large for production usage. This can be caused by high variation in a key step in the assay, as was the case in the NPY2 assay, but it may also be caused by excessive variation in the individual observations, an insufficient number of concentrations, or poor statistical estimation techniques in deriving the potency estimates. High variation in the individual observations can be identified through signal window or Z′ factor calculations and then addressed through experimental designs to further optimize the assay. The latter 2 can be addressed by use of optimal statistical analysis methods. Figure 2B indicates an assay with high interrun variability. The MSR is 1.86, which is quite acceptable for most applications, but because the confidence limits for the MR do not include 1.0, there is a statistically significant systematic difference between runs. In particular, the MR is 2.25, which indicates that values in run 1 are on average 2.25 times less potent than those in run 2. This pattern indicates that the assay lacks robustness. Figure 3A shows the analysis for the 1st replicate-experiment study. The MSR estimate of 122.4 and the LsA of 0.00 to 55.2 match the poor agreement between the runs discussed above. The results for the 2nd replicate-experiment study are shown in Figure  3B . The results are substantially better, with an MSR of 1.60, much improved over the 1st study. The most potent values showed the poorest agreement, indicating possibly the need to adjust the po- Screening 11(3); 2006 www.sbsonline.org 257
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FIG. 2. (A)
This example replicate-experiment study illustrates high intrarun assay variability. The minimum significant ratio = 4.72, and the limits of agreement = (0.16-3.63) (short dashed lines), which is too variable for many production assays. The mean ratio is 0.77, which is not statistically different from 1.0, as the ratio limits (long dashed lines) include the value 1. (B) This example replicate-experiment study illustrates high interrun variability. The minimum significant ratio = 1.86, which is acceptable, but the mean ratio = 2.25 and is statistically higher than 1.0, as the ratio limits (long dashed lines) exclude the value 1. Comparisons of compounds across 2 or more assay runs will be affected by this interrun variability.
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tency range for compounds with IC 50 values less than 10 nM. There was a 42% systematic difference between the 2 runs (MR = 1.42), which was statistically significant (ratio limits exclude 1.0). The magnitude of the discrepancy was not large and could be due to comparing IC 50 s instead of K i s, which were not available. The LsA (0.88-2.27) assess the combined effect of intrarun and interrun variation, and with values this tight, it was recommended to move the assay into production.
Assay acceptance criteria and sample size
Eastwood and others 5 conducted extensive simulations to determine suitable acceptance criteria and an appropriate number of compounds for the replicate-experiment protocol. The results indicate assay acceptance criteria should be based on the MSR and LsA statistics and not on the MR statistic or ratio limits. In particular, an assay is acceptable if the MSR is small enough and both the LsA are close to 1.0. Exact cutoff values necessarily depend on the usage of the assay. Assays used to estimate potency at the desired biological target often have much more stringent requirements than assays used to ascertain selectivity or off-target activity. Assays used early in the drug development process often have less stringent requirements than assays used in the later stages of drug development. Thus, unlike screening criteria, it is not possible to determine a priori a universal acceptance criterion.
As an example of practical implementation, in our company, we have set general acceptance criterion for assays of an MSR ≤3 and LsA between 0.33 and 3.0 (i.e., both numbers must be between 0.33 and 3.0). The sample size should be 20 to 30 compounds. Exceptions are made depending on resource constraints and assay usage. For the NPY2 assay, the assay had to meet the standard requirements. Clearly, the 1st test failed to meet these requirements, whereas the 2nd test passed them.
The MSR and LsA values are themselves estimates of underlying population parameters, and the precision of these estimates depends on the sample size used. Of the 2 parameters, the MSR is the more sensitive to sample size. The results by Eastwood and others 5 indicate that for a sample size of 20 to 30 compounds, the MSR estimate from a replicate-experiment study will be within 50% of the population MSR 95% of the time. The LsA estimates conversely are more sensitive to the underlying intrarun and interrun assay variation and are less affected by moderate changes in sample size.
5
LABORATORY TRANSFER
Replicate-experiment protocol for laboratory transfer
When transferring an assay to a new lab, it is important to verify that the new lab is producing equivalent estimates to the existing laboratory's assay. Assays are equivalent if there is no systematic difference between the assays and both assays are sufficiently reliable so that there is no material difference in individual compound estimates between the 2 assays. To examine these requirements, a series of compounds should be tested in a single run of the assay by both laboratories. As with the (within-laboratory) replicateexperiment protocol, we recommend 20 to 30 compounds covering the potency range of interest. This we term the transfer protocol, and it is essentially the same study recommended by Bland and Altman 6 when comparing 2 clinical devices. Because the laboratory just starting the assay will normally be just validating the assay for usage, the 2 protocols can be combined by having the existing laboratory run the compounds a single time and the new laboratory run the set of compounds twice in 2 independent runs.
The between-lab analysis uses 1 run from the existing laboratory and the 1st run in the new laboratory. It proceeds exactly as with the replicate-experiment protocol. The only difference is in the interpretation and utility of the outcomes. In this protocol, the MR and LsA are the most important outcomes. The MSR value in this protocol is actually a function of the assay variability of both laboratories and is not a directly interpretable parameter. Thus, it is not used in this protocol. The MR statistic and corresponding 95% ratio limits are used to test for a difference in average potency across laboratories. Ratio limits not containing 1 indicate a statistically significant difference, and the MR statistic estimates the average fold ratio between laboratories. The LsA indicate the bounds of agreement in individual compound results. Upper and lower limits that are significantly different than those obtained by a within-laboratory replicateexperiment study indicate differences in assay variation between laboratories. Note, however, that this assessment must be made along visual and material grounds. There is no simple statistical test for differences in assay variability across laboratories. However, with additional data pulled from the current laboratory, it is possible to construct a test for differences in laboratory variation. See Eastwood 12 for details.
Factor Xa assay laboratory transfer
These methods were applied to an assay transfer for a factor Xa (fXa) enzyme inhibition assay. The assay existed for many years in a discovery laboratory, and it was desired to transfer it to a highvolume screening laboratory. To establish the equivalence of the assays in each laboratory, the transfer protocol was conducted by having each laboratory assay 21 compounds. Then, to establish that the new (screening) laboratory achieved acceptable precision in the potency estimates, researchers conducted the replicate-experiment protocol by reassaying the compounds a 2nd time. Discussions with the team, including chemistry and biology disciplines, suggested an MSR ≤3 was considered acceptable.
Materials: fXa inhibition
Human fXa was purchased from Enzyme Research Laboratories (South Bend, IN). Chromogenic para-nitroanilide-substrate Bz-Ile-Glu-Gly-Arg-pNA was purchased from Midwest Biotech (Fishers, IN) .
Binding affinity for fXa
The apparent K ass values were obtained in a high-volume testing protocol [13] [14] [15] using automated dilutions of inhibitors (performed in triplicate at 4-8 inhibitor concentrations) into 96-well plates and chromogenic substrate hydrolysis rates determined at 405 nm using a Thermomax plate reader from Molecular Devices (San Francisco, CA). The assay protocol was 50 µl buffer (0.06 M tris, 0.3 M NaCl, pH 7.4), 25 µl inhibitor test solution (in MeOH), 25 µl human fXa (32 nM in 0.03 M tris, 0.15 M NaCl, 1 mg/ml HSA), and, finally, 150 µl substrate (0.3 mM in water) added within 2 min to start hydrolysis. The final fXa was 3.2 nM. Free Xa and bound Xa were determined from linear standard curves on the same plate by use of SoftmaxPro software, and the apparent K ass was calculated for each inhibitor concentration, which produced hydrolysis inhibition between 20% and 80% of the control: apparent
. The variability of mean apparent K ass values determined at the single substrate concentration was ±15%. The assay system K m was measured as 0.347 ± 0.031 mM (n = 4); Vmax was 13.11 ± 0.76 µM/min. Values were converted to K i values according to the formula K i = 1000/K ass . Figures 4A and 4B show the ratio-geometric mean plots and statistics for the interrun and intrarun results for the fXa assay transfer and validation. The results indicate excellent reliability in the new assay, with an MSR of 1.71 and a 7% difference across runs (not significant). There is also excellent agreement across laboratories with LsA = 0.54 to 2.02 and confidence limits for the average ratio in run potencies of 0.9 to 1.21. Thus, the assay transfer equivalence has been established, and the new assay is ready to replace the existing one.
FXa results
Table 5 contains the K i estimates, and
DISCUSSION
Replicate-experiment studies can be used to establish acceptable assay performance during the life of the assay. Initially, as in the NPY2 example, a replicate-experiment protocol can be used when the assay is first developed to estimate the MSR, the key outcome of statistical reliability of concentration-response assays. Then, as assays are transferred to new laboratories or undergo 16 and Sun and others 7 used a Bland-Altman analysis to compare 2 assays. In this article, we adapt the analysis to estimate the MSR using 2 runs of a single assay, an approach not used in those articles or in the original Bland-Altman article. 6 Our approach to laboratory transfer stresses the need to assess the equivalence of the laboratory variation and not just estimate a multiplier to compare results across the labs. We also express the assay variation and all plots as potency ratios rather than differences in log potency. We have found that users find this extension very useful as it translates a rather difficult-to-interpret parameter, σ, into a parameter that is directly useful in SAR work. Sun and others also described a protocol of 5 experiments with 3 compounds to estimate the assay variation, whereas we describe a protocol of 2 experiments of 20 to 30 compounds. In practice, there are numerous variants that can adequately estimate the required parameter. The advantage of our protocol is the rapid determination of the answer: 2 experiments that are very similar to production runs of the assay. In addition, because more compounds are employed, the result may generalize better to the variation obtained when testing new chemical entities. Conversely, Sun and others' protocol will be advantageous when there are only a few standards available.
We agree with Sun and others 7 that there are no absolute criteria to define acceptable performance; each assay has to be individually judged according to the needs of the users based on the needs for the assay, the nature of the SAR, and the willingness of the users to adopt risks of misclassification of structure relationships. But although there is not 1 value to universally use as an acceptance criterion, a value can be determined by each project team to judge the acceptability of an assay for its proposed use in the project. Also, an important advantage of having an estimate of the MSR is that one can then use it to judge the relationship between structure and potency. Being able to judge those structural comparisons that are real potency differences versus those that are consistent with normal assay variation is an essential requirement of SAR work. Note that the replicate-experiment protocol MSRs are for comparing 2 compounds evaluated within the same physical run. Normally, molecules are evaluated across 2 or more runs, and across-run comparisons are usually more variable than comparisons within the same run. Therefore, users should be aware of this property when setting acceptance criteria for MSRs and assessing structural relationships. Methods to estimate the MSR that incorporates run-to-run variation are in progress.
Unlike statistics such as the correlation coefficient, the MSR and LsA do not depend on the actual potencies of the compounds. 5 However, especially when using the transfer protocol, it is important to have a wide range of potencies to establish that there are no potency-dependent trends across assays. In the replicateexperiment protocol, it is important that the assay variability be visually assessed across a range of potencies to check for uniformity of assay variation. For example, in the NPY2 assay, compounds with the lowest potencies tended to have the poorest agreement between runs, suggesting the estimation limits for the concentration range were being reached. Compounds that are too potent for the concentration range used need to be reevaluated with a left shift in the concentration range.
Ideally, the compounds should be selected to have uniform spacing on the log scale over the potency range of the assay. For example, if the concentration range of the assay runs from 0.1 nM to 10 µM, then the IC 50 values of the compounds should uniformly cover this range. In practice, uniformity is difficult to achieve, as there may not exist compounds with this distribution or the potencies of the compounds in the assay may be imperfectly known. In A B that case, it would be preferred to choose more compounds at the more potent end of the potency range, as occurred in our fXa inhibition example. Both the MSR and MR are sensitive to outlier results. In the fXa example, an outlier ratio occurred in the least potent compound. In this example, even with the outlier result, the assay performance is acceptable. If that were not the case, then the results should be checked without the outlier to ascertain the sensitivity of the conclusions to the outlier. However, unlike outlier responses from readings of single wells, which are commonly caused by equipment malfunctions, an outlier potency estimate derived from a concentration-response curve is less likely to be due to a single aberrant well (especially if the fitting procedure down-weights or removes outlier values). In this example, the outlier occurred at a very low potency, and so it would be appropriate to remove the value in this case, as it is lower than the intended range of the assay.
Replicate-experiment studies have the limitation that they establish the acceptability of the assay at the time they were conducted. They in no way guarantee that an acceptable assay will maintain continued performance during the time of use. That can be done only with ongoing quality control procedures.
Another problem that may occur when running both the replicate-experiment and transfer protocols is that the MSR is acceptably low but the LsA in the transfer protocol are too high. This combination indicates that the original assay has unacceptable within-run variation, which may not be a problem. If the change to the assay were intended to improve the assay, then this would be a desirable outcome. Normally, little effort should be devoted to further examining or improving the old assay, and instead, one should identify which compounds need to be reevaluated in the new assay.
